| 63.55 1.22 (1.96%) | 04-19 11:12 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 76.21  |
1-year : | 89.02 |
| Resists | First : | 65.25 |
Second : | 76.21 |
| Pivot price | 60.6 |
|||
| Supports | First : | 59.8 |
Second : | 56.43 |
| MAs | MA(5) : | 61.31 |
MA(20) : | 60.25 |
| MA(100) : | 61.42  |
MA(250) : | 71 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 70.7 |
D(3) : | 68.3 |
| RSI | RSI(14): 57.1 |
|||
| 52-week | High : | 100.85 | Low : | 50.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LNTH ] has closed below upper band by 8.3%. Bollinger Bands are 67% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 63 - 63.31 | 63.31 - 63.61 |
| Low: | 60.56 - 60.94 | 60.94 - 61.32 |
| Close: | 60.77 - 61.38 | 61.38 - 61.98 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Thu, 18 Apr 2024
Why Lantheus Holdings Inc's Stock Skyrocketed 11% in a Quarter - GuruFocus.com
Wed, 17 Apr 2024
Andrea Sabens Sells 341 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock - MarketBeat
Wed, 17 Apr 2024
Lantheus Holdings (LNTH) Dips More Than Broader Markets: What You Should Know - Yahoo News Australia
Tue, 16 Apr 2024
Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by DekaBank Deutsche Girozentrale - Defense World
Tue, 16 Apr 2024
Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Arizona State Retirement System - Defense World
Mon, 15 Apr 2024
Lantheus Holdings (LNTH) Stock Moves -0.89%: What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 69 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 104.7 (%) |
| Shares Short | 4,720 (K) |
| Shares Short P.Month | 5,220 (K) |
| EPS | 4.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.9 |
| Profit Margin | 25.2 % |
| Operating Margin | 42.4 % |
| Return on Assets (ttm) | 21.2 % |
| Return on Equity (ttm) | 51.7 % |
| Qtrly Rev. Growth | 34.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 18.96 |
| EBITDA (p.s.) | 8.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 305 (M) |
| Levered Free Cash Flow | 156 (M) |
| PE Ratio | 13.4 |
| PEG Ratio | 0.2 |
| Price to Book value | 5.23 |
| Price to Sales | 3.28 |
| Price to Cash Flow | 13.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|